Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Gross Margin (2017 - 2022)

Acro Biomedical has reported Gross Margin over the past 6 years, most recently at 17.78% for Q4 2022.

  • Quarterly results put Gross Margin at 17.78% for Q4 2022, down 731.0% from a year ago — trailing twelve months through Sep 2023 was 17.78% (down 749.0% YoY), and the annual figure for FY2022 was 21.34%, down 33.0%.
  • Gross Margin for Q4 2022 was 17.78% at Acro Biomedical, down from 25.63% in the prior quarter.
  • Over the last five years, Gross Margin for ACBM hit a ceiling of 29.65% in Q1 2021 and a floor of 6.25% in Q4 2019.
  • Median Gross Margin over the past 5 years was 16.0% (2021), compared with a mean of 16.81%.
  • Biggest five-year swings in Gross Margin: skyrocketed 648bps in 2021 and later plummeted -731bps in 2022.
  • Acro Biomedical's Gross Margin stood at 10.0% in 2018, then plummeted by -38bps to 6.25% in 2019, then soared by 271bps to 23.17% in 2020, then rose by 8bps to 25.08% in 2021, then dropped by -29bps to 17.78% in 2022.
  • The last three reported values for Gross Margin were 17.78% (Q4 2022), 25.63% (Q1 2022), and 25.08% (Q4 2021) per Business Quant data.